External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Biological Segment Impacted by Regulatory Changes: PI Industries’ domestic business reported 6% YoY growth in Q1FY26, reaching Rs 339 Cr, with domestic revenue excluding biologicals rising by 13% YoY.</li><li>Revenue from biological products declined ~38% YoY due to regulatory changes in Jun’25, which impacted sales across the industry.</li><li>Additional challenges included cash flow pressures from fertiliser shortages, low commodity prices, and elevated channel inventory.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Biological Segment Impacted by Regulatory Changes: PI Industries’ domestic business reported 6% YoY growth in Q1FY26, reaching Rs 339 Cr, with domestic revenue excluding biologicals rising by 13% YoY.Revenue from biological products declined ~38% YoY due to regulatory changes in Jun’25, which impacted sales across the industry.Additional challenges included cash flow pressures from fertiliser shortages, low commodity prices, and elevated channel inventory.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PI Industries Ltd - Facing Headwinds on Multiple Fronts; Downgrade to HOLD

Pi Industries

PI Industries Ltd - Facing Headwinds on Multiple Fronts; Downgrade to HOLD